465 related articles for article (PubMed ID: 15000529)
21. Interaction of synaptotagmin with voltage gated calcium channels: a role in Lambert-Eaton myasthenic syndrome?
David P; Martin-Moutot N; Leveque C; el Far O; Takahashi M; Seagar MJ
Neuromuscul Disord; 1993; 3(5-6):451-4. PubMed ID: 8186692
[TBL] [Abstract][Full Text] [Related]
22. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
[TBL] [Abstract][Full Text] [Related]
23. Lambert-Eaton syndrome antibodies inhibit acetylcholine release and P/Q-type Ca2+ channels in electric ray nerve endings.
Satoh Y; Hirashima N; Tokumaru H; Takahashi MP; Kang J; Viglione MP; Kim YI; Kirino Y
J Physiol; 1998 Apr; 508 ( Pt 2)(Pt 2):427-38. PubMed ID: 9508807
[TBL] [Abstract][Full Text] [Related]
24. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
[TBL] [Abstract][Full Text] [Related]
25. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
26. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome.
Takamori M; Takahashi M; Yasukawa Y; Iwasa K; Nemoto Y; Suenaga A; Nagataki S; Nakamura T
J Neurol Sci; 1995 Nov; 133(1-2):95-101. PubMed ID: 8583238
[TBL] [Abstract][Full Text] [Related]
27. Lambert-Eaton Myasthenic Syndrome.
Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
[TBL] [Abstract][Full Text] [Related]
28. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
Hülsbrink R; Hashemolhosseini S
Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
[TBL] [Abstract][Full Text] [Related]
29. Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels.
Spillane J; Ermolyuk Y; Cano-Jaimez M; Lang B; Vincent A; Volynski KE; Kullmann DM
Neurology; 2015 Feb; 84(6):575-9. PubMed ID: 25589670
[TBL] [Abstract][Full Text] [Related]
30. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
31. Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome.
Verschuuren JJ; Dalmau J; Tunkel R; Lang B; Graus F; Schramm L; Posner JB; Newsom-Davis J; Rosenfeld MR
Neurology; 1998 Feb; 50(2):475-9. PubMed ID: 9484375
[TBL] [Abstract][Full Text] [Related]
32. Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy.
Takamori M
Biochem Biophys Res Commun; 2004 Oct; 322(4):1347-51. PubMed ID: 15336982
[TBL] [Abstract][Full Text] [Related]
33. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
34. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Titulaer MJ; Lang B; Verschuuren JJ
Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
[TBL] [Abstract][Full Text] [Related]
35. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
Takamori M
Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
[TBL] [Abstract][Full Text] [Related]
36. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
[TBL] [Abstract][Full Text] [Related]
37. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction.
Peers C; Johnston I; Lang B; Wray D
Neurosci Lett; 1993 Apr; 153(1):45-8. PubMed ID: 8390031
[TBL] [Abstract][Full Text] [Related]
38. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
39. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies.
Sanders DB
Ann Neurol; 1995 May; 37 Suppl 1():S63-73. PubMed ID: 8968218
[TBL] [Abstract][Full Text] [Related]
40. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
